Lipid Controls
Avanti Polar Lipids 16:0-18:1 PG 200MG16:0-18:1 P
1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt). 268550-95-4
Avanti Polar Lipids DOPE; 18:1 (9CIS) PE, 1G
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine. 4004-05-1
![Medchemexpress LLC Poly(oxy-1,2-ethanediyl), α-[(9R)-6-hydroxy-6-oxido-1,12-dioxo-9-[(1-oxooctadecyl)oxy]-5,7,11-trioxa-2-aza-6-phosphanonacos-1-yl]-ω-[2-[(3-carboxy-1-oxopropyl)amino]ethoxy]- | 1445832-74-5 | 99.95% | 2000 (Average) | 5 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000384511-logo.png-250.jpg){kind=logo}
Medchemexpress LLC Poly(oxy-1,2-ethanediyl), α-[(9R)-6-hydroxy-6-oxido-1,12-dioxo-9-[(1-oxooctadecyl)oxy]-5,7,11-trioxa-2-aza-6-phosphanonacos-1-yl]-ω-[2-[(3-carboxy-1-oxopropyl)amino]ethoxy]- | 1445832-74-5 | 99.95% | 2000 (Average) | 5 MG
DSPE-PEG (2000)-COOH is a pegylated derivative of 1,2-Distearoyl-sn-glycero-3-phosphorylethanolamine. It can form micelles for targeted drug delivery.
- Can form micelles for targeted drug delivery
- Appearance: solid
- Color: white to off-white
eMolecules BP Lipid 800 | Broadpharm |858.340 | C50H99NO9 | 85.000 | CCCCCCCCC(CCCCCCCC)OC(=O)CCOCCOCCN(CCO)CCOCCOCCC(=O)OC(CCCCCCCC)CCCCCCCC | 10mg | 718091575
BP Lipid 800 | Broadpharm |858.340 | C50H99NO9 | 85.000 | CCCCCCCCC(CCCCCCCC)OC(=O)CCOCCOCCN(CCO)CCOCCOCCC(=O)OC(CCCCCCCC)CCCCCCCC | 10mg | 718091575
Avanti Polar Lipids 16:0 PEG2000 PE | 474922-84-4 | MFCD02262261 | 25mg
16:0 PEG2000 PE | Purity: 99% | Mol Wt: 2749.42 | 474922-84-4 | MFCD02262261 | 25mg
![Medchemexpress LLC Poly(oxy-1,2-ethanediyl), α-[(9R)-6-hydroxy-6-oxido-1,12-dioxo-9-[(1-oxooctadecyl)oxy]- | 1445832-74-5 | 99.95% | 2000 (Average) | 25 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000385579-logo.png-250.jpg){kind=logo}
Medchemexpress LLC Poly(oxy-1,2-ethanediyl), α-[(9R)-6-hydroxy-6-oxido-1,12-dioxo-9-[(1-oxooctadecyl)oxy]- | 1445832-74-5 | 99.95% | 2000 (Average) | 25 MG
DSPE-PEG (2000)-COOH is a pegylated derivative of 1,2-Distearoyl-sn-glycero-3-phosphorylethanolamine. This compound is capable of forming micelles for targeted drug delivery.
- Can form micelles for targeted drug delivery
- Useful for polyvalent targeted delivery of vinorelbine to cancer cells
- Can be used as optical coherence tomography contrast agents for tumor angiography in live animals
- Targets liposome
- Pathway: Metabolic enzyme/protease
- Powder stable at -20°C for 3 years
- In solvent stable at -80°C for 6 months, and at -20°C for 1 month
- Solubility in H2O: 25 mg/mL (requires ultrasonic treatment)
- Solubility in DMSO: 25 mg/mL (requires ultrasonic, warming, and heating to 60°C)
- Achieves a clear solution at ≥ 2.5 mg/mL in specific in vivo solvent combinations
- For research use only
Dc Chemicals Limited D-Lin-MC3-DMA | 1224606-06-7 | 642.1 g/mol | 25MG
D-Lin-MC3-DMA | 1224606-06-7 | 642.1 g/mol | 25MG
Avanti Polar Lipids 18:1 CY7 PE CHLOROFORM
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(Cyanine 7)
Avanti Polar Lipids C16 LACTOSYL(B) CERAMIDE 5MG
C16 Lactosyl(ß) Ceramide (d18:1/16:0) 5mg 4201-62-1 MFCD08703001 Molecular Formula C46H87NO13, Purity>99%, Formula Weight 862.182